Sean Wuxiong Cao sold $80k of NBP
Chief Bus. Development Officer at NovaBridge Biosciences. 107,978 shares at an average of $0.74, traded Sep 9, 2026, filed Sep 11, 2026.
Score components
- +15RoleOfficer
- +9Trade size$80k at market
- +10Share of holdings soldSold 29% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002109966-26-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | SOpen-market sale Ordinary Shares | -107,978 | $0.74 | $80k | 266,467 | 32 d ago |
Related signals
Other insiders at NovaBridge Biosciences and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 8Weak | NovaBridge Biosciences | Phillip Andrew Dennis Chief Medical Officer | $5,828 8,209 shares | -5% | |
| 8Weak | NovaBridge Biosciences | Cong Claire Xu EVP, Clinical Development | $2,593 3,282 shares | -1% | |
| 0Weak | NBPsell NovaBridge Biosciences | Phillip Andrew Dennis Chief Medical Officer | $5,606 8,494 shares | -5% | |
| 31Weak | NBPsell NovaBridge Biosciences | Sean Wuxiong Cao See Remarks | $43k 21,399 shares | -38% | |
| 50Moderate | NBPbuy NovaBridge Biosciences | Mark Arnold Hagler See Remarks | $577k 230,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.